Dr. Uri Tabori’s research focuses on pediatric neural tumours, which are the main cause of death from childhood cancer. He is examining telomerase, an enzyme that is active in small populations of cells in pediatric neural tumours, and has observed that normal cells are less dependent on telomerase for self-renewal. His project is entitled “Exhaustion of tumour initiating cells by targeting their self-renewal capacity with telomerase inhibition.”
Dr. Tabori’s research will build on Principal Investigator Dr. Rob Rottapel’s Selective Therapies Target Identification program. Dr. Rottapel’s team is developing cancer therapies that target and destroy cancer cells without harming healthy cells. Their work is designed to develop more effective treatments and reduce patient side effects.
Mentoring Program: Terry Fox Translational Program in Selective Therapies Target Identification
Mentors/PIs: Dr. Robert Rottapel